Search the Community
Showing results for tags 'viral'.
Found 3 results
Jefferson Adams posted an article in Celiac Disease & Gluten Intolerance ResearchCeliac.com 07/28/2016 - Celiac disease is an immune-mediated enteropathy triggered by gluten in genetically susceptible individuals. Researchers know that innate immunity plays a role in triggering celiac disease, but they don't understand the connection very well at all. Although previous in vitro work suggests that gliadin peptide p31-43 acts as an innate immune trigger, the underlying pathways are unclear and have not been explored in vivo. The research team included RE Araya, MF Gomez Castro, P Carasi, JL McCarville, J Jury, AM Mowat, EF Verdu, and FG Chirdo. They are variously affiliated with the Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP)(CONICET-UNLP), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Argentina; the Catedra de Microbiología, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Argentina; the Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada; the Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom; and with the Instituto de Estudios Inmunológicos y Fisiopatológicos (IIFP)(CONICET-UNLP), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Argentina. Their team observed that introduction of p31-43 into the gut of normal mice causes structural changes in the small intestinal mucosa consistent with those seen in celiac disease, including increased cell death and expression of inflammatory mediators. The effects of p31-43 were dependent on MyD88 and type I IFNs, but not Toll-like receptor 4 (TLR4), and were enhanced by co-administration of the TLR3 agonist polyinosinic:polycytidylic acid. Together, these results indicate that gliadin peptide p31-43 activates celiac-related innate immune pathways in vivo, such as IFN-dependent inflammation. These findings also suggest a common mechanism for the potential interaction between dietary gluten and viral infections in the pathogenesis of celiac disease, meaning that certain viral infections may pave the way for celiac disease to develop. Source: Am J Physiol Gastrointest Liver Physiol. 2016 Jul 1;311(1):G40-9. doi: 10.1152/ajpgi.00435.2015. Epub 2016 May 5.
Jefferson Adams posted an article in Additional Celiac Disease ConcernsCeliac.com 11/15/2016 - The YouTube video that helped to spark litigation against blood pressure drug Olmesartan, also marketed as Benicar, was made by celiac disease expert Dr. Joseph Murray, a gastroenterologist and a professor of medicine at the Mayo Clinic in Rochester, New York, who is very familiar with the drug's side effects. In July 2013, the U.S. Food and Drug Administration (FDA) issued a warning to patients and doctors that the popular blood pressure medication Benicar had been linked to a severe side effect called sprue-like enteropathy. The side effect was easily confused with celiac disease or a gluten sensitivity, and caused serious problems in many patients, including cases of irreparable gut damage. A week after the FDA's warning, Dr. Joseph Murray took to YouTube to notify patients about the drug's risks. In the video, Dr. Murray advises anyone who is taking Benicar, and who has also been diagnosed with celiac disease, to consult a doctor about the FDA warning. Many Benicar patients learned the hard way the drug can cause debilitating side effects, but Dr. Murray's video no doubt helped spread awareness to patients who suffer from sprue-like enteropathy. Many patients feel Benicar's manufacturer, Daiichi Sankyo, failed to warn consumers of the risks associated with the drug and are now trying to hold the company responsible through legal action. There are more than 1,700 lawsuits currently pending against the company. Plaintiffs have called into question the validity of the clinical trial leading to Benicar's approval with the FDA. Managing high blood pressure is a long-term proposition, but the clinical trial testing Benicar's safety and efficacy only lasted three months. Plaintiffs believe the short clinical trial caused the makers to overlook the risk of sprue-like enteropathy, but plaintiffs are also pointing to the fact that drug maker Daiichi Sankyo spent $1 billion on Benicar advertising between 2002 and 2008. The plaintiffs say that company advertising focused more on the benefits of Benicar, while downplaying potential risks. The suit has been slate for court docket in 2017. Stay tuned for developments on this and related matters.
In the Friday, February 9, 1996 edition of the Independent newspaper (UK), there was a short article reporting research into ME (myalgic encephalomyelitis) by doctors at the Royal Hallamshire Hospital in Sheffield. Their research was published that same weeks Lancet. Mysterious symptoms, including muscle weakness, wasting, and poor coordination and balance may be due to an undiagnosed allergy to wheat, barley, oats or rye, according to new research which may have implications for some people with ME...A study of 53 patients with these and other unexplained neurological symptoms, found that nearly three-fifths of them had antibodies to gluten in their blood...none of the patients in the Sheffield group had been diagnosed with celiac disease but when samples of tissue were removed from their gut, more than a third showed evidence of the disease or inflammation of the middle and lower gut.